Orexo Appoints Nomination Committee for 2025 AGM
UPPSALA, Sweden - The Nomination Committee for Orexo's upcoming Annual General Meeting (AGM) has officially been appointed. This committee is crucial in guiding key decisions for the company's future.
Meet the Nomination Committee
The members of the Nomination Committee include industry veterans who bring a wealth of experience and expertise. The appointed members are:
- Henrik Kjaer Hansen (Chairman, appointed by Novo Holdings A/S)
- Claus Berner Møller (appointed by The Danish Labour Market Supplementary Pension, ATP)
- Stefan Hansson (private investor)
- James Noble (Chairman of the Board of Orexo)
Collectively, these individuals represent about 34 percent of the voting shares in Orexo. Their diverse backgrounds and strong leadership skills will help steer significant proposals for the AGM.
Function of the Nomination Committee
The primary role of the Nomination Committee is to prepare vital proposals for the AGM. This includes recommendations for the Chairman of the meeting, the Chairman of the Board, Board members, their salaries, and fees for committee work, as well as remuneration for the auditing process.
Shareholders Invited to Contribute
Orexo encourages shareholders to participate actively in the Nomination process. Shareholders wishing to provide their own recommendations can reach out to the committee via email. It’s important to note that submissions should be made no later than the specified deadline.
About Orexo
Orexo is a renowned Swedish pharmaceutical company with decades of experience focused on creating advanced pharmaceuticals using proprietary formulation technologies. The company is committed to addressing substantial medical needs, particularly in the area of opioid use disorders, through innovative treatment solutions.
In the United States, Orexo develops and provides groundbreaking products that assist patients in managing their conditions related to opioid use disorder and adjacent conditions. The company partners with leading organizations worldwide to develop additional therapeutic solutions, thereby expanding its impact in the global market.
In terms of performance, Orexo showcased robust results, achieving total net sales reaching SEK 639 million in 2023, complemented by a dedicated workforce of 116 employees. Orexo is publicly traded on the Nasdaq Stockholm main list and appears as an ADR on OTCQX (ORXOY) in the USA.
Business Outlook
As Orexo continues its growth trajectory, its ongoing commitment to research and development remains a priority. This focus not only aims to enhance existing treatment options but also seeks to venture into new therapeutic areas that serve unmet needs. By collaborating with other key industry players, Orexo is set to expand its portfolio and enhance healthcare outcomes.
Continuous Improvement
The forthcoming AGM is a pivotal moment for Orexo as it solidifies its governance and strategic direction. The discussions held there could shape the company’s path forward significantly, especially in navigating the complexities of the pharmaceutical landscape.
Frequently Asked Questions
What is the Nomination Committee's role?
The Nomination Committee prepares proposals for key roles and remuneration for the AGM, influencing significant company decisions.
Who are the current members of the Nomination Committee?
The current members include Henrik Kjaer Hansen, Claus Berner Møller, Stefan Hansson, and James Noble.
How can shareholders submit proposals?
Shareholders can submit proposals by emailing the Nomination Committee before the specified deadline.
What are Orexo's key markets?
Orexo is focused on the US market for opioid use disorder and is developing products for other therapeutic areas globally.
What is Orexo's financial performance?
Orexo reported total net sales of SEK 639 million in 2023, reflecting its strong market position and commitment to growth.
